The Limited Times

Now you can see non-English news...

AstraZeneca: $ 1.17 billion raised with the anti-Covid vaccine in the first half


Sales represented $ 572 million in Europe and $ 455 million in emerging countries according to the Swedish-British group.

Pharmaceutical company AstraZeneca announced Thursday that sales of its Covid-19 vaccine reached $ 1.17 billion in the first half of the year, and raised its forecast.

This figure corresponds to the delivery of approximately 319 million doses worldwide.

Sales represented $ 572 million in Europe, and $ 455 million in emerging countries, according to a statement from the Swedish-British group.

To read also: Vaccination: deliveries of Pfizer down and AstraZeneca shunned by the French

Group sales over the period increased 23% year-on-year to $ 15.5 billion and net profit group share rose 40% to $ 2.1 billion.

The group stresses that progress in its developing product portfolio and the recent acquisition of Alexion support its longer-term growth.

AstraZeneca is raising its earnings forecast for the full year to reflect the contribution of Alexion, whose acquisition has just been completed.


AstraZeneca generated a new period of strong growth thanks to a solid performance in all regions and in all pathologies

", particularly in oncology, said CEO Pascal Soriot.

Read also: Covid-19: Can Sanofi's vaccine still be useful?

The Swedish-British pharmaceutical group announced in mid-July that it had obtained the green light from the United Kingdom for its $ 39 billion acquisition of the American biotech Alexion, which specializes in rare diseases.

Source: lefigaro

All business articles on 2021-07-29

You may like

Trends 24h

Business 2021-09-22T20:56:12.297Z


© Communities 2019 - Privacy